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Introduction
Patients with juvenile idiopathic arthritis (JIA) com-
monly have been using methotrexate (MTX) to improve
the clinical course of the disease, however non adher-
ence is frequently observed.
Objectives
To evaluate the reason for MTX interruption, if it was
due therapeutic inefficacy or side effects.
Methods
Data were collected from medical charts of JIA patients
followed at the pediatric rheumatology Unit from the
State University of Campinas. Relevant clinical variables
was observed as age, gender, age at diagnosis, subtype of
JIA, age at start of MTX, the time from diagnosis to start
the treatment with MTX (in months), response to MTX
(yes / no) and whether there were adverse effects (yes /
no) and the reason for discontinuation of MTX.
Results
We included 98 patients (median age 15.4 ± 7.5 years)
who had a definitive diagnosis of JIA and used MTX.
Seventy-six (78%) patients were females. The JIA subtype
most frequently observed was polyarticular. Routes of
administration of MTX observed were subcutaneous
(55%) and oral (13%), but many patients throughout the
treatment used both administration (32%) in order to
improve adherence to treatment. After a mean follow-up
time of 5 years, 51 (52%) of these patients discontinued
treatment and 47 (48%) of them were still on treatment,
but only 35 (74%) were adherent. Sixty-eight (69%) JIA
patients reported the presence of sporadic episodes of
adverse reactions during treatment. Episodes of adverse
reactions related to MTX was mainly gastric intolerance
(abdominal discomfort, nausea and vomiting). There
were three cases of elevated transaminase levels and one
case of neutropenia. The reasons for JIA patients discon-
tinue treatment with MTX was presence of side effects
(35%), interruption on their own decision (27%), treat-
ment abandonment (12%) and other reasons such as
pregnancy, chickenpox and lack of medication in the
public hospitals (12%), improvement of the disease (8%),
and inefficacy (6%). All patients who discontinued MTX
on their own decision had additionally the presence of
side effects.
Conclusion
Although MTX has a great therapeutic index, the side
effects are still seen as a major form of abandonment of
this pharmacological treatment. Therefore a careful his-
tory is essential to identify side effects and adequate
treatment to increase adherence.
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